Teva Targets $113 Billion In Branded Sales With Dozens Of Pending Applications
The Israeli drug maker reports sales rose by 25 percent in 2009, and takes aim at a plethora of generic opportunities
The Israeli drug maker reports sales rose by 25 percent in 2009, and takes aim at a plethora of generic opportunities